IPSOGEN signed in 2008 a license agreement with Université Libre de Bruxelles (ULB), Belgium for the worldwide and exclusive rights on the Genomic Grade™.

IPSOGEN is involved in several clinical studies in breast cancers with main cancer centres and institutes, incl. Institut Curie, and Institut Paoli-Calmettes. It continues to work with Institut Jules Bordet to further refine the potential of the Genomic Grade test.

Interested in a collaboration with IPSOGEN in breast cancers?
Please contact us.